AVIR

Atea Pharmaceuticals, Inc. (AVIR) | Rumor.io

Atea Pharmaceuticals

AVIR

Attention (50-day avg)0%

Attention rank (50-day avg)#3,589

Bullish sentiment (50-day avg)100%

Price to earnings ratio-2.69

Market capitalization417.1M

Earnings per share-2.08

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-158.3M

Social

What share of all stock conversation is about AVIR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 28

Atea Pharmaceuticals' Phase 3 C-BEYOND trial met both its primary and secondary endpoints, evaluating bemnifosbuvir/ruzasvir for Hepatitis C Virus.
The company's once-daily fixed-dose combination of bemnifosbuvir/ruzasvir showed positive topline Phase 3 results in North America, with data from a second study due early next year.
Analysts are expected to raise target prices for Atea Pharmaceuticals, potentially leading to a significant increase in the stock's value.

Generated by AI

Sentiment

Of the messages about AVIR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +33.33	85.96% +8.79
Bearish	—	—	0% -33.33	14.04% -8.79

Bullish· Nov 5

The company has a strong cash position with $860 million in cash, which could be used to fund future developments and drive growth.
The asset has a low float, making it susceptible to short squeezes, and the author is confident that it will at least double in price from its current level.
The company's pill has shown benefits in high-risk adults, similar to Pfizer's pill, and the author believes that Roche and Atea are committed to the program and will not give up easily.

Bearish· Nov 18

Atea Pharmaceuticals' ($AVIR) partnership may be on shaky ground, with the company potentially facing financial issues and the possibility of money being called back.
The company's phase 3 trial is not enough to prevent a significant price drop, with the stock expected to fall further.
A downgrade by SVB Leerink to Market Perform from Outperform, with a new price target of $11, suggests a significant decrease in the stock's value.

Generated by AI

Topics

Of the messages about AVIR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	92.93%
Analysts	—	—	0%	1.01%
Controversies	—	—	0%	5.05%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	1.01%

Analysts· Oct 20

JP Morgan downgraded Atea Pharmaceuticals to Neutral from Overweight and cut the price target to $16 from $61, citing a "challenging path forward".
SVB Leerink cut the price target for Atea Pharmaceuticals to $20 from $60, but maintained an "outperform" rating, after the company's Phase 2 trial did not meet its primary endpoint.
Atea Pharmaceuticals has a buy consensus of 92% among 5 analysts, with an average price target of $37.6.

Announcements· May 10

Atea Pharmaceuticals reported a GAAP EPS of -$0.51 for Q1 2022, beating estimates by $0.05.
The company announced Q1 2022 financial results and provided a business update on May 10, 2022.
Revenue for Q1 2022 was $42.07M.

Technical Analysis· Oct 20

$AVIR needs to break $14.50 for the next leg up.
$AVIR is oversold and extremely overbought, with a bullish engulfing candle forming.
$AVIR has a cup and handle forming, and a short squeeze is expected if it breaks through $14.

Generated by AI

Community

Of the messages about AVIR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	26.78%
Newcomers	—	—	100%	73.22%

Regulars· Jul 28

The Phase 3 C-BEYOND trial evaluating Atea Pharmaceuticals' bemnifosbuvir/ruzasvir combination for hepatitis C virus met both its primary and secondary endpoints.
The asset's efficacy is comparable to the comparator, but the absolute number is not high, and the treatment's 8-week efficacy appears to be affected by the cost.
Analysts are expected to raise the target price for Atea Pharmaceuticals' stock following the positive Phase 3 trial results.

Newcomers· Jul 23

Newcomers to the asset are experiencing significant losses, with some mentioning that their accounts are "bleeding" and they're feeling emotional pain.
The pain of being a bagholder is a common theme, with users expressing regret, heartbreak, and feelings of being stuck in a losing trade.
The price drop of AVIR is a major concern for these newcomers, with some users describing the experience as "pure pain" and others feeling like they're "bleeding out" due to the losses.

Generated by AI

Also Discussed

Investors talking about AVIR also mention

#	Name	Attention
1	Cocrystal Pharma, Inc.COCP	0%new
2	Vir Biotechnology, Inc.VIR	0%+0
3	HARP - Harpoon Therapeutics, Inc.	——
4	Protagonist Therapeutics, Inc.PTGX	0%new
5	Prelude Therapeutics IncorporatedPRLD	0%0
6	Raymond James Financial Inc.RJF	0%0
7	Forte Biosciences, Inc.FBRX	0%new
8	Fulcrum Therapeutics, Inc.FULC	0%0
9	GRTX - Galera Therapeutics, Inc.	——
10	EAR - Eargo, Inc.	——

Atea Pharmaceuticals, Inc.

Healthcare
Biotechnology

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapies for serious viral infections. Atea Pharmaceuticals’ current programs center on treatments for hepatitis C, including a late-stage regimen combining bemnifosbuvir and ruzasvir, as well as broader antiviral research across other RNA virus targets. The company also works on therapies for hepatitis E and other viral diseases, reflecting its emphasis on unmet medical needs in infectious disease. Its portfolio is designed around small-molecule oral medicines, which are intended to support convenient outpatient treatment options and address diseases that can require long-term or difficult-to-administer care. Based in Boston, Massachusetts, Atea Pharmaceuticals operates in the biopharmaceutical sector, where antiviral drug development plays a significant role in advancing treatment choices for patients and healthcare providers.

Website

Location

225 Franklin Street

Boston, MA, 02110

United States

Social

What share of all stock conversation is about AVIR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 28

Atea Pharmaceuticals' Phase 3 C-BEYOND trial met both its primary and secondary endpoints, evaluating bemnifosbuvir/ruzasvir for Hepatitis C Virus.
The company's once-daily fixed-dose combination of bemnifosbuvir/ruzasvir showed positive topline Phase 3 results in North America, with data from a second study due early next year.
Analysts are expected to raise target prices for Atea Pharmaceuticals, potentially leading to a significant increase in the stock's value.

Generated by AI

Sentiment

Of the messages about AVIR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +33.33	85.96% +8.79
Bearish	—	—	0% -33.33	14.04% -8.79

Bullish· Nov 5

The company has a strong cash position with $860 million in cash, which could be used to fund future developments and drive growth.
The asset has a low float, making it susceptible to short squeezes, and the author is confident that it will at least double in price from its current level.
The company's pill has shown benefits in high-risk adults, similar to Pfizer's pill, and the author believes that Roche and Atea are committed to the program and will not give up easily.

Bearish· Nov 18

Atea Pharmaceuticals' ($AVIR) partnership may be on shaky ground, with the company potentially facing financial issues and the possibility of money being called back.
The company's phase 3 trial is not enough to prevent a significant price drop, with the stock expected to fall further.
A downgrade by SVB Leerink to Market Perform from Outperform, with a new price target of $11, suggests a significant decrease in the stock's value.

Generated by AI

Topics

Of the messages about AVIR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	92.93%
Analysts	—	—	0%	1.01%
Controversies	—	—	0%	5.05%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	1.01%

Analysts· Oct 20

JP Morgan downgraded Atea Pharmaceuticals to Neutral from Overweight and cut the price target to $16 from $61, citing a "challenging path forward".
SVB Leerink cut the price target for Atea Pharmaceuticals to $20 from $60, but maintained an "outperform" rating, after the company's Phase 2 trial did not meet its primary endpoint.
Atea Pharmaceuticals has a buy consensus of 92% among 5 analysts, with an average price target of $37.6.

Announcements· May 10

Atea Pharmaceuticals reported a GAAP EPS of -$0.51 for Q1 2022, beating estimates by $0.05.
The company announced Q1 2022 financial results and provided a business update on May 10, 2022.
Revenue for Q1 2022 was $42.07M.

Technical Analysis· Oct 20

$AVIR needs to break $14.50 for the next leg up.
$AVIR is oversold and extremely overbought, with a bullish engulfing candle forming.
$AVIR has a cup and handle forming, and a short squeeze is expected if it breaks through $14.

Generated by AI

Community

Of the messages about AVIR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	26.78%
Newcomers	—	—	100%	73.22%

Regulars· Jul 28

The Phase 3 C-BEYOND trial evaluating Atea Pharmaceuticals' bemnifosbuvir/ruzasvir combination for hepatitis C virus met both its primary and secondary endpoints.
The asset's efficacy is comparable to the comparator, but the absolute number is not high, and the treatment's 8-week efficacy appears to be affected by the cost.
Analysts are expected to raise the target price for Atea Pharmaceuticals' stock following the positive Phase 3 trial results.

Newcomers· Jul 23

Newcomers to the asset are experiencing significant losses, with some mentioning that their accounts are "bleeding" and they're feeling emotional pain.
The pain of being a bagholder is a common theme, with users expressing regret, heartbreak, and feelings of being stuck in a losing trade.
The price drop of AVIR is a major concern for these newcomers, with some users describing the experience as "pure pain" and others feeling like they're "bleeding out" due to the losses.

Generated by AI

Atea Pharmaceuticals

Social

Jul 28

Sentiment

Bullish· Nov 5

Bearish· Nov 18

Topics

Analysts· Oct 20

Announcements· May 10

Technical Analysis· Oct 20

Community

Regulars· Jul 28

Newcomers· Jul 23

Also Discussed

Atea Pharmaceuticals, Inc.

Company Information

Location

Also Discussed

Social

Jul 28

Sentiment

Bullish· Nov 5

Bearish· Nov 18

Topics

Analysts· Oct 20

Announcements· May 10

Technical Analysis· Oct 20

Community

Regulars· Jul 28

Newcomers· Jul 23